2021 Çѱ¹Á¤½Å½ÅüÀÇÇÐȸ Ãá°èÇмú´ëȸ ¹× ¿¬¼ö±³À° : 2021-05-28±³À°ÀÏÀÚ : 2021-05-28
±³À°Àå¼Ò : ¹é¹ü±è±¸±â³ä°ü ÄÁ¹ê¼ÇȦ,´ëȸÀǽÇ
±³À°ÁÖÁ¦ :
2021 Çѱ¹Á¤½Å½ÅüÀÇÇÐȸ Ãá°èÇмú´ëȸ ¹× ¿¬¼ö±³À°ÁÖÃÖ±â°ü : Çѱ¹Á¤½Å½ÅüÀÇÇÐȸ
´ã´çÀÚ : °íÀº¾ç
¿¬¶ôó : 051-255-6902
À̸ÞÀÏ :
sericonf@daum.net ±³À°Á¾·ù : Á¤½Å°Ç°ÀÇÇаú
Âü¼®¿¹»óÀοø : 100¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 10 ½Ã°£ 50ºÐ
¼¼ºÎ¼ö°·á : 50,000¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 05-28 Ä˺¥¼ÇȦ 09:30~09:50 Understanding of medically unexplained symptoms ¹ÚÇý¿¬(¼¿ïÀÇ´ë)
±³À°½Ã°£ 05-28 Ä˺¥¼ÇȦ 09:50~10:10 Diagnosis and evaluation of somatic symptom disorder Àå½ÂÈ£(¿ø±¤ÀÇ´ë)
±³À°½Ã°£ 05-28 Ä˺¥¼ÇȦ 10:10~10:30 Management of somatic symptom disorder ÀüÈ«ÁØ(°Ç±¹ÀÇ´ë)
Åä·Ð 05-28 Ä˺¥¼ÇȦ 10:30~10:40 Q & A ()
±³À°½Ã°£ 05-28 Ä˺¥¼ÇȦ 10:50~11:15 Psychotic disorders due to medical illnesses ±è¼º¹Î(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 05-28 Ä˺¥¼ÇȦ 11:15~11:40 Mood disorders due to medical illnesses ÃÖ°ü¿ì(°í·ÁÀÇ´ë)
Åä·Ð 05-28 Ä˺¥¼ÇȦ 11:40~11:50 Q & A ()
±³À°½Ã°£ 05-28 Ä˺¥¼ÇȦ/´ëȸÀÇ½Ç 12:00~12:20 A retrospective study of the effect of background factors on seizure quality in ECT, Nobuatsu Aoki(Department of Neuropsychiatry Kansai Medical University)
±³À°½Ã°£ 05-28 Ä˺¥¼ÇȦ/´ëȸÀÇ½Ç 12:20~12:40 Serum CK levels in 72 patients with malignant syndrome, rhabdomyolysis, and water intoxication Hidenori Matsunaga(Division of PsychiatryOsaka General Medical Center)
±³À°½Ã°£ 05-28 ÄÁº¥¼ÇȦ 12:50~13:15 Psychedelic Drugs: Lessons From SPRAVATO À̹®¼ö(°í·ÁÀÇ´ë)
±³À°½Ã°£ 05-28 ÄÁº¥¼ÇȦ 13:15~13:40 SPRAVATO clinical ting &real practice for TRD/MDSI patients °¿ø¼·(°æÈñÀÇ´ë)
Åä·Ð 05-28 ÄÁº¥¼ÇȦ 13:40~13:50 Q&A ()
±³À°½Ã°£ 05-28 ÄÁº¥¼ÇȦ 14:00~14:25 Effects of contraception on psychiatric problem À±¼¿µ(´ë±¸°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 05-28 ÄÁº¥¼ÇȦ 14:25~14:50 Hormonal background and treatment of perinatal depression ±è¼±¹Ì(Áß¾Ó´ëÇб³º´¿ø)
±³À°½Ã°£ 05-28 ÄÁº¥¼ÇȦ 14:50~15:15 Cognition and mood in perimenopausal women À̼ÒÈñ(±¹¸³Áß¾ÓÀÇ·á¿ø)
Åä·Ð 05-28 ÄÁº¥¼ÇȦ 15:15~15:30 Q & A ()
±³À°½Ã°£ 05-28 ÄÁº¥¼ÇȦ 15:50~16:15 EAP »ç¾÷ÀÇ ¿î¿µ °æÇè°ú ½ÇÁ¦ ±èÁ¤Çö(ºÐ´ç ¼¿ï´ëº´¿ø)
±³À°½Ã°£ 05-28 ÄÁº¥¼ÇȦ 16:15~16:40 Á÷ÀåÀÎ Á¤½Å°Ç°°ü¸®ÀÇ ½ÇÁ¦ : °ø°ø Á¤½Å º¸°Ç ¿µ¿ªÀ» Áß½ÉÀ¸·Î °ÇÑ°íÀººñ(±¹¸³³ªÁÖº´¿ø)
±³À°½Ã°£ 05-28 ÄÁº¥¼ÇȦ 16:40~17:05 ±â¾÷ÀÇ Á÷ÀåÁ¤½Å°Ç° °ü¸® ¹æ¾ÈÀÇ ½ÇÁ¦ Àü»ó¿ø(°ºÏ»ï¼ºº´¿ø ±â¾÷Á¤½Å°Ç°¿¬±¸¼Ò)
Åä·Ð 05-28 ÄÁº¥¼ÇȦ 17:05~17:20 Q & A ()
±³À°½Ã°£ 05-28 ´ëȸÀÇ½Ç 12:50~13:15 Differential Benefits of BUSPAR È«Á¤¿Ï(Àͻ꺴¿ø)
±³À°½Ã°£ 05-28 ´ëȸÀÇ½Ç 13:15~13:40 The usefulness of buspirone in treatment somatic symptoms Àå½ÂÈ£(¿ø±¤ÀÇ´ë)
Åä·Ð 05-28 ´ëȸÀÇ½Ç 13:40~13:50 Q&A ()
±³À°½Ã°£ 05-28 ´ëȸÀÇ½Ç 14:00~14:25 Cancer mortality ±èÇöÁø(Ãæ³²ÀÇ´ë)
±³À°½Ã°£ 05-28 ´ëȸÀÇ½Ç 14:25~14:50 Drug-related mortality in psychiatric patients ±è±â¿ø(Áß¾Óº¸Èƺ´¿ø)
±³À°½Ã°£ 05-28 ´ëȸÀÇ½Ç 14:50~15:15 Mortality in schizophrenia and bipolar disorder ±èÁØÇü(°í·ÁÀÇ´ë)
Åä·Ð 05-28 ´ëȸÀÇ½Ç 15:15~15:30 Q & A ()
±³À°½Ã°£ 05-28 ´ëȸÀÇ½Ç 15:50~16:15 Àü°øÀÇ Âü¿© º´µ¿consult¿¡¼ÀÇ Å¸°ú¿ÍÀÇ ÀÇ»ç¼ÒÅë ±èż®(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 05-28 ´ëȸÀÇ½Ç 16:15~16:40 ÀÀ±Þ½Ç¿¡¼ÀÇ Å¸°ú¿ÍÀÇ ÀÇ»ç ¼ÒÅë ÃÖÀç¿ø(À»ÁöÀÇ´ë)
±³À°½Ã°£ 05-28 ´ëȸÀÇ½Ç 16:40~17:05 ¹Ù²î´Â ¼ö·Ãȯ°æ ÇÏ¿¡¼ ÇÊ¿äÇÑ Àü°øÀÇ ¼ö·Ã ¹æ½Ä º¯È ¿ÀÈ«¼®(°Ç¾ç´ë)
Åä·Ð 05-28 ´ëȸÀÇ½Ç 17:05~17:20 Q & A ()